Skip to Main Content

Paper Details

A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.
JAMA Surg
46
2021
Cancer, Early-Stage Lung Adenocarcinoma, LUAD, PRecur, Participants, SMARCA4, TP53, cancer, genome, lung adenocarcinoma, patients, stages I to III LUAD, tumor, tumor genomic, women
Author NameAffiliation
Ronglai ShenMemorial Sloan Kettering Cancer Center
Ronglai ShenDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Francisco VegaCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Michael F BergerCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Nikolaus SchultzCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Nikolaus SchultzCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Hira RizviDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Hira RizviMemorial Sloan Kettering Cancer Center
Gregory J RielyDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Gregory J RielyMemorial Sloan Kettering Cancer Center
Gregory J Riely
Marc LadanyiDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Marc LadanyiMemorial Sloan Kettering Cancer Center
Marcin Imielinski
  • 1 - 14

Datasets

Release 1.2